<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03373929</url>
  </required_header>
  <id_info>
    <org_study_id>17-2871</org_study_id>
    <nct_id>NCT03373929</nct_id>
  </id_info>
  <brief_title>Stitch Closure of PFO and Septal Repair</brief_title>
  <acronym>STITCH</acronym>
  <official_title>Suture Mediated Septal Defect Closure/Repair Evaluation of the NobleStitch EL System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HeartStitch.Com</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HeartStitch.Com</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the STITCH study is to evaluate closure rates of clinically relevant septal
      defects, including patent foramen ovale (PFO), Atrial Septal Defects (ASD - less than 1 cm
      with redundant septal tissue), trans septal puncture sites, repair of Atrial Septal Aneurysm
      (ASA) and rate of recurrent neurologic embolic events in patients with cryptogenic stroke and
      PFO.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Anticipated">November 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Non-randomized, single-center, observational study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Closure Rates of PFO and ASD</measure>
    <time_frame>12 months</time_frame>
    <description>Saline Contrast Echo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent Stroke Rate</measure>
    <time_frame>4-6 weeks, 6 months, 1 year and annually up to five years</time_frame>
    <description>Rate of which Patient Experiences Recurrent Stroke</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Migraine</measure>
    <time_frame>4-6 weeks, 6 months, 1 year and annually up to five years</time_frame>
    <description>Rate of Patients who have Experienced Improvement in Migraine</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Foramen Ovale, Patent</condition>
  <condition>Septal Defect, Atrial</condition>
  <condition>Septal Defect, Heart</condition>
  <arm_group>
    <arm_group_label>PFO Closure Rate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Evaluate closure rate of clinically relevant septal defects including PFO, ASD (less than 1 cm with redundant septal tissue), trans septal puncture sites, repair of ASA (when an appropriate PFO or small ASD defect is present) and rate of recurrent neurologic embolic event in patients with cryptogenic stroke and PFO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Published PFO Device Closure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Compare PFO closure rate and safety of closure of septal occluders in published PFO clinical trials.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PFO Closure Rate</intervention_name>
    <description>Suture Mediated PFO Closure and Septal Repair</description>
    <arm_group_label>PFO Closure Rate</arm_group_label>
    <arm_group_label>Published PFO Device Closure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Published PFO Device Closure</intervention_name>
    <description>Suture Mediated PFO Closure and Septal Repair</description>
    <arm_group_label>PFO Closure Rate</arm_group_label>
    <arm_group_label>Published PFO Device Closure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PFO

          -  ASD (less than 1 cm with redundant septal tissue)

          -  Trans Septal Puncture Sites

          -  ASA (when an appropriate PFO or small ASD defect is present)

          -  Stroke

          -  Trans ischemic Attack (TIA)

          -  Platypnea Orthodeoxia Syndrome

          -  Decompression Illness

        Exclusion Criteria:

          -  Patients under 18 and over 65

          -  Patients who are not fluent in English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Thompson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inova Cardiovascular Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inova Cardiovascular Institute</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>HeartStitch.Com</investigator_affiliation>
    <investigator_full_name>James Thompson, MD</investigator_full_name>
    <investigator_title>Interventional Cardiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Septal Defects</mesh_term>
    <mesh_term>Heart Septal Defects, Atrial</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

